SUMMARY

• Phillip Reece is a consultant expert with over 30 years experience in the research and development of human pharmaceuticals
• Trained in organic chemistry at the University of Adelaide and medical chemistry at the Australian National University, Canberra
• Undertook clinical pharmacology research at the Queen Elizabeth Hospital, an Adelaide University teaching hospital, for 12 years before joining Astra Pharmaceuticals, Sydney in 1987
• Appointed Director of Clinical Pharmacology, Parke Davis, Ann Arbor, MI, USA in 1990 and responsible for the development of CNS drugs.
• Appointed Director of Research and Development in 1993 at Biota Holdings, one of Australia’s leading biotechnology companies and founder of the influenza antiviral, zanamivir
• Since 2002 held several senior industry roles including CEO of Boron Molecular, a fine chemicals company, Chairman of Cryptopharma, an early stage biotechnologycompany developing new antiinflammatory drugs, and non-executive Director of EnGeneIC, a privately held company developing a new vehicle for delivering anticancer drugs
• Acted as a consultant expert to lawyers engaged in one of Australia’s largest commercial litigation cases. This involved communicating complex scientific issues to the legal team, assisting in the preparation of questions for expert witnesses, and preparing technical reports, chronologies and literature reviews for the case
• Consultant expert in the areas of pharmaceutical development, clinical trials, pharmacokinetics, pharmacodynamics and intellectual property matters to biotechnology companies, pharmaceutical companies and law firms
• 64 scientific publications in the areas of human pharmacokinetics, clinical trials, respiratory antivirals particularly for influenza, anticancer drugs and antihypertensives; 3 book chapters on antihypertensives and an inventor on three published patents in the area of respiratory antivirals 

EMPLOYMENT

Current

May 03 – present: Consultant to the biotechnology industry
Dec 03 – present :Senior Fellow (Honorary), Department of Pharmacology, University of Melbourne, Melbourne

Previous

Feb 04 – Nov 08 Consultant to Biota Holdings, Melbourne
Dec 03 – Apr 08 Non-executive Chairman, Cryptopharma Pty Ltd, Melbourne
Mar 02 – May 03 CEO and Managing Director, Boron Molecular Ltd, Melbourne
Dec 01 – Mar 02 General Manager, Australian Operations, Biota Holdings, Melbourne
May 01 – Mar 02 Non-executive Director, Biota Inc, Carlsbad, CA, USA
Dec 00 – Feb 09 Non-executive Director, EnGeneIC Pty Ltd, Sydney
July 94 – May 95 Acting CEO, Biota Holdings, Melbourne
Oct 93 –  Dec 01 Director, Research and Development, Biota Holdings, Melbourne
Aug 90 – Sep 93 Director, Clinical Pharmacology, Parke Davis Ltd, Ann Arbor MI, USA
Sep 98 – Aug 90 Associate Regional Director, Clinical Research, Parke Davis, Sydney
Sep 87 – Sep 88 Clinical Trials Manager, Astra Pharmaceuticals, Sydney
Feb 83 – Sep 87 Chief Hospital Scientist, The Queen Elizabeth Hospital, Adelaide
Dec 75 – Feb 83 Principal Hospital Scientist, The Queen Elizabeth Hospital, Adelaide